IDH1 and central nervous system cancer: The 2021 WHO CNS Classification recently stratified most IDH-mutant GBM into astrocytoma, WHO grade 413. Numerous studies have shown that the presence of IDH1 mutation serves as a predictive biomarker for TMZ sensitivity in low-grade gliomas and secondary GBM42,43.